Pharmacotherapy of multiple myeloma: An economic perspective

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 4, 2003, Pages 515-524

  Messori, Andrea ^a   Trippoli, Sabrina ^a   Santarlasci, Benedetta ^a  

^a Centro Informazione Farmaci   (Italy)

Author keywords

Autologous transplantation; Cost effectiveness; Melphalan; Multiple myeloma; Thalidomide

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; INTERFERON; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

AUTOTRANSPLANTATION; BONE PAIN; CANCER PAIN; CANCER RECURRENCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; EUROPE; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; UNITED STATES;

AGED; COST-BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; EXPERT TESTIMONY; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THALIDOMIDE;

EID: 0037398438     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.4.515     Document Type: Review

References (62)

1. RAJKUMAR SV, GERTZ MA, KYLE RA, GREIPP PR et al.: Current therapy for multiple myeloma. Mayo Clin. Proc. (2002) 77:813-822.
2. WEBER DM: Newly diagnosed multiple myeloma. Curr. Treat. Options Oncol. (2002) 3(3):235-245.
3. CAMPBELL K: Myeloma: its diagnosis and treatment. Nurs. Times (2002) 98(26):38-40.
4. ATTAL M, HAROUSSEAU JL, STOPPA AM et al.: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. (1996) 335:91-97.
5. SEGEREN CM, SONNEVELD P, VAN DER HOLT B et al.: Overall and event free survival are not improved by the use of myelo-ablative therapy following intensifies chemotherapy in previously untreatd multiple myeloma patients: a prospective randomized Phase III study. Blood (2002) (In press).
6. LENHOFF S, HJORTH M, HOLMBERG E et al.: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood (2000) 95(1):7-11.
7. RAJKUMAR SV, HAYMAN S, GERTZ MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. (2002) 20(21):4319-4323.
8. WEBER D, RANKIN K, GAVINO M, DELASALLE K, ALEXANIAN R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. (2003) 21(1):16-19.
9. HJORTII M, HOLMBERG E, RODIER S et al.: Survival in conventionally treated younger (< 60 years) multiple myeloma patients: no improvement during two decades. Eur. J. Haematol. (1999) 62:271-277.
10. Combination chemotherapy versus: melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. The Myeloma Trialists' Collaborative Group. J. Clin. Oncol. (1998) 16:3832-3842.
11. TRIPPOLI S, MESSORI A, BECAGLI P, ALTERINI R, TENDI E: Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation. Oncology Reports (1998) 5:1475-1482.
12. VESOLE DH, CROWLEY JJ, CATCHATOURIAN R et al.: High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group Phase II trial. J. Clin. Oncol. (1999) 17(7):2173-2179.
13. RAJKUMAR SV, FONSECA R, LACY MQ et al: Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. (1999) 23(12):1267-1272.
14. KOVACSOVICS TJ, DELALY A: Intensive treatment strategies in multiple myeloma. Semin. Hematol. (1997) 34(1 Suppl. 1):S49-S60.
15. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. The Myeloma Trialists' Collborative Group. Br. J. Haematol. (2001) 113(4):1020-1034.
16. ALEXANIAN R, DIMOPOULOS MA, DELASALLE K, BARLOGIE B: Primary dexamethasone treatment of multiple myeloma. Blood (1992) 80(4):887-890.
17. BERENSON JR, CROWLEY JJ, GROGAN TM et al.: Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma. Blood (2002) 99(9):3163-3168.
18. MEHTA J, TICOT G, JAGANNATH S et al.: Salvage autologous or allogenic transplantation for multiple myeloma refractory to or relpsing after a first-line autograft? Bone Marrow Transplant. (1998) 21(9):887-892.
19. MOEHLER TM, NEBEN K, BENNER A et al.: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood (2001) 98(13):3846-3848.
20. FOSSA A, MUER M, KASPER C, WELT A, SEEBER S, NOWROUSIAN MR: Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia (1998) 12(3):422-426.
21. MINEUR P, MENARD JF, LE LOET X et al.:VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br. J. Haematol. (1998) 103(2):512-517.
22. GERTZ MA, KALISH LA, KYLE RA, HAHN RG, TORMEY DC, OKEN MM: Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alpha-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am. J. Clin. Oncol. (1995) 18(6):475-480.
23. CELESTI I, CLAVIO M, POGGI A, CASCIARO S, VALLEBELLA E, GOBBI M: The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients. Haematologica (1997) 82(3):351-353.
24. SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 342(5):364.
25. HUS M, DMOSZYNSKA A, SOROKA-WOJTASZKO M et al: Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica (2000) 86(4):404-408.
26. BARLOGIE B, DESIKAN R, EDDLEMON P et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood (2001) 98(2):492-494.
27. YAKOUB-AGHA I, MOREAU P, LEYVRAZ S et al.: Thalidomide in patients with advanced multiple myeloma. Hematol. J. (2000) 1(3):186-189.
28. TOSI P. ZAMAGNI E, CELLINI C et al.: Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 87(4):408-414.
29. PALUMBO A, GIACCONE L, BERTOLA A: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica (2001) 86(4):399-403.
30. COLOMBI M, GUFFANTI A, ALIETTI A et al: OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma. Leuk. Lymphoma (2000) 40(1-2):87-94.
31. DIMOPOULOS MA, ZERVAS K, KOUVATSEAS G et al: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. (2001) 12(7):991-995.
32. BARLOGIE B, VESOLE DH, JAGANNATH S: Salvage therapy for multiple myeloma: the University of Arkansas experience. Mayo Clin. Proc. (1994) 69(8):787-795.
33. MUNSHI NC, TRICOT G, DESIKAN R et al: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia (2002) 16(9):1835-1837.
34. MAJOR P, LORTHOLARY A, HON J et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. (2001) 19(2):558-567.
35. LONGO D: Plasma cell disorders. In: Harrison's Principles of Internal Medicine, Volume 1, (14th Edn.), McGraw Hill, USA (1998):712-717.
36. GOLDSCHMIDT H, HEGENBART U, WALLMEIER M, HOHAUS S, HAAS K: Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br. J. Haematol. (1997) 98(3):736-744.
37. MOREAU P, FACON T, ATTAL M et al.: Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myeloma 9502 randomized trial. Blood (2002) 99(3):731-735.
38. GULBRANDESEN N, WISLOFF F, BRINCH L et al.: Health-related quality of life in multiple myeloma. patents receiving high-dose chemotherapy with autologous blood stem-cell support. Med. Oncol. (2001) 18(1):65-77.
39. SHUSTIK C: Interferon in the treatment of multiple myeloma. Cancer Control (1998) 5:226-234.
40. 2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. (1990) 322:1430-1434.
41. BROWMAN GP, BERGSAGEL D, SICHERI D et al: Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol (1995) 13:2354-2360.
42. 2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. Br. J. Haematol. (1995) 89(3):561-568.
43. SALMON SE, CROWLEY JJ, GROGAN TM, FINLEY P, PUGH RP, BARLOGIE B: Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: a Southwest Oncology Group study. J. Clin. Oncol. (1994) 12(11):2405-2414.
44. PEEST D, DEICHER H, COLDEWEY R et al: A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur. J. Cancer. (1995) 31A(2):146-151.
45. LUDWIG H, COHEN AM, POLLIACK A et al.: Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomised trials and summary of other studies. Ann. Oncol. (1995) 6(5):467-476.
46. CUNNINGHAM D, POWLES R, MALPAS J et al: A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long term follow-up results. Br. J. Haematol, (1998) 102(2):495-502.
47. WISLOFF F, GULBRANDSEN N: Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group. Acta Oncol. (2000) 39(7):809-813.
48. MCCLOSKEY EV, DUNN JA, KANIS JA, MACLENNAN IC, DRAYSON MT: Longterm follow-up of a prospective, doubleblind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br. J. Haematol. (2001) 113(4):1035-1043.
49. BERENSON JR, HILLNER BE, KYLE RA et al: American Society of clinical oncology clinical practice guidelines: the role of bisposphonates in multiple myeloma. J. Clin. Oncol. (2002) 20(17):3719-3736.
50. GULBRANDESEN N, WISLOFF F, NORD E et al: Cost-utility of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur. J. Haematol. (2001) 66(5):328-336.
51. SAMPSON FC, BEARD SM, SCOTT F, VANDENBERGHE E: Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br. J. Haematol, (2001) 113(4):1015-1019.
52. 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial. Pharmacoeconomics (1997) 12(1):89-103.
53. TRIPPOLI S, BECAGLI P, MESSORI A et al.: Maintenance treatment with interferon in multiple myeloma. Clin. Drug Invest. (1997) 14:392-399.
54. WISLOFF F, GULBRANDSEN N NORD E: Therapeutic options in the treatment of multiple myeloma. Pharmacoeconomic and quality of life considerations. Pharmacoeconomics (1999) 16(4):329-341.
55. LENHOFF S, TURESSON I, HJORTH M et al: Intensive therapy in newly diagnosed multiple myeloma patients below 60 years: a prospective, controlled, population based study. The nordic myeloma study group. Blood (1998) 92:727a (Abstract).
56. DE ARRIBA F, HERAS I, DEL CARMEN GARCIA M et al.: Economic costs of autotransplantation of hematopoietic progenitors. Med. Clin. (1996) 106(9):329-332.
57. AGER S, SCOTT MA, MAHENDRA P et al: Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant. (1995) 16:79-83.
58. UYL-DE GROOT CA, OKHUIJSEN SY, HAGENBEEK A et al: Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant. (1995) 15(4):605-610.
59. SCHULMAN KA: Economics of bone marrow transplantation. J. Clin. Oncol. (1996) 14(5):1409-1410.
60. SMITH TJ, HILLNER BE, SCHMITZ N et al.: Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15(1):5-10.
61. MESSORI A, TRIPPOLI S, VAIANI M: Efficacy, safety, and cost of new anticancer drugs. Price needs to be evaluated against effectiveness. BMJ (2002) 325(7375):1302.
62. VESOLE DH, SIMIC A, LAZARUS HM: Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts. Bone Marrow Transplant. (2001) 28(8):725-735.